Glufosfamide threshold brain delivery
WebSep 28, 2006 · Last month the Company announced that it had completed enrollment in a pivotal phase 3 clinical trial evaluating glufosfamide for the potential second-line treatment of pancreatic cancer and a phase 2 clinical trial evaluating glufosfamide in combination with gemcitabine for the potential first-line treatment of pancreatic cancer. WebMar 19, 2008 · Indication. Investigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma. Build, train, & validate predictive machine-learning models with structured datasets. See how. Contraindications & Blackbox Warnings.
Glufosfamide threshold brain delivery
Did you know?
Glufosfamide, being a conjugate of glucose and active alkylating moiety of ifosfamide, has the better cell permeability than the parent compound — ifosfamide — or its metabolites. Glufosfamide utilizes the normal cell glucose transport mechanism (a sodium-dependent glucose/sodium co-transporter) for its own transport into the cell. And the glucose uptake mechanism is grossly overexpressed and upregulated in certain cancer cell lines, especially pan… WebMar 2, 2007 · To evaluate the safety of weekly glufosfamide dosing in subjects with ovarian cancer as compared with every 21-day dosing. Secondary objectives: To evaluate the efficacy of glufosfamide in subjects with ovarian cancer as measured by objective response rate, duration of response, progression-free survival, and overall survival.
WebOct 3, 2006 · The Phase III trial will evaluate approximately 300 previously treated patients with locally advanced and/or metastatic pancreatic cancer who receive best supportive … WebJul 28, 2007 · Glufosfamide (Threshold Pharmaceuticals, Redwood City, CA) is a new cytotoxic alkylating agent prodrug in which isophosphoramide mustard (IPM) is glycosidically linked to β-D-glucose. ... Patients were excluded from the study if they had previously received gemcitabine, if they had symptomatic brain metastases, radiation therapy …
WebIn this way, glufosfamide targets cancer cells while reducing toxicity to normal cells. Glufosfamide has been evaluated in more than 450 patients in multiple clinical studies … WebMTD of glufosfamide administered every 28 days in combi-nation with standard dose gemcitabine administered weekly for 3 weeks of every 4 week cycle. Glufosfamide was admin-istered intravenously over 4 h on day 1 of every 4-week cycle. Glufosfamide doses started at 1,500 mg/m2 and esca-lated to 2,500, 3,500 and 4,500 mg/m2 in cohorts of three
WebDec 1, 2003 · Discussion. Glufosfamide showed a low hematological and non-hematological toxicity profile in GBM patients. The relatively large volume that was administrated in a short time (1000 ml in 60 min) did not cause increased edema or neurological deterioration during or shortly after the infusion, events that have been …
WebGlufosfamide was compared to best supportive care on 303 randomised patients. There was an 18% increase in OS for glufosfamide that was not statistically significant: HR = 0.85, [0.66–1.08]; P = 0.19) [75]. A randomised phase II study evaluated raltitrexed with … A.L. Inselman, D.K. Hansen, in Encyclopedia of Toxicology (Third … Corinna Weber-Schöndorfer, Christof Schaefer, in Drugs During Pregnancy … In Meyler's Side Effects of Drugs (Sixteenth Edition), 2016. Organs and systems … The glycoconjugate drug (glufosfamide) exhibited 4.5-fold decreased toxicity in … lian li m205WebOct 3, 2006 · October 3, 2006. Threshold Pharmaceuticals announced that under the FDA has granted orphan drug designation to the company's product candidate, glufosfamide, for the treatment of pancreatic cancer. Orphan drug designation is intended to encourage research and development of new therapies for diseases that affect fewer than 200,000 … lian li itxWebBrain and Central Nervous System Tumors (1) Carcinoma, Small Cell Lung (1) Lung Cancer (1) ... Threshold Pharmaceuticals (3) Sign Up. Intervention New. glufosfamide (9) fluorouracil (1) gemcitabine (1) Study Results. Has … banana pet sim x valueWebJan 31, 2005 · Our data suggests that a disfunction in glutamate-glutamine cycle in the brain may play a role in the pathophysiology of schizophrenia. Elevated … lian li open airWebJan 18, 2008 · Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that … banana slippers jokeWebDec 28, 2006 · Glufosfamide was generally well tolerated in combination with gemcitabine with no new unexpected adverse events. "We are pleased with these encouraging top-line results and look forward next year to additional six- and twelve-month survival data from this clinical trial," said Barry Selick, Ph.D., Threshold's chief executive officer. lian linWebApr 2, 2024 · These efforts have led to several targeting strategies that modulate drug delivery in both the preclinical and clinical settings, including small molecule-, nucleic acid-, peptide-, antibody-, and cell-based strategies. Here, we discuss key advances and emerging concepts for tissue-specific drug delivery approaches and their clinical … lian li odyssey x silver